Given Imaging Third Quarter Revenues Exceed $7.4 Million
480% Increase over third quarter 2001

15 October 2002 - Yoqneam, Israel -- Given Imaging (NASDAQ: GIVN) announced today that sales of its Given® Diagnostic Imaging System and M2A video capsule exceeded $7.4 million in the third quarter of 2002. This represents a 480% increase over sales generated in the third quarter of 2001. For the first nine months of 2002, sales exceed $19.8 million.

"We continue to be pleased at the progress we are making globally with our Given capsule endoscope which is changing the way that gastroenterologists diagnose and treat their patients," said Gavriel D. Meron, president and chief executive officer of Given Imaging.

Fourth Quarter Conference Call Details
Given Imaging expects to release its third quarter financial results on October 30, 2002. In conjunction with the release of earnings, the Company will host a conference call on October 31, 2002, 10:00 am EST, which will be broadcast live on Given Imaging’s web site at www.givenimaging.com.

This press release contains forward-looking statements, including projections about our business, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the future tense, words such as "anticipates," "estimates," "expects," "intends," "plans," "believes," "intends" and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are not guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, and other risks disclosed in our filings with the U.S. Securities Exchange Commission.

19.Sept.'03